Company No: 04091037 (England and Wales)

Contents

• Company Information
• Balance Sheet
• Notes to the Financial Statements

DIRECTORS	Dr Curtis Hamman
	Robert Hodkinson
	Nicholas Plunkett

REGISTERED OFFICE	Worlds End Studios 132-134
	Lots Road
	London
	SW10 0RJ
	United Kingdom

COMPANY NUMBER

04091037 (England and Wales)

ACCOUNTANT	Gravita Business Services II Limited
	Aldgate Tower
	2 Leman Street
	London
	E1 8FA
	United Kingdom

		2024		2023
		£		£
Fixed assets		9,090		18,916
Current assets		163,390		198,715
Prepayments and accrued income		7,731		16,411
Creditors: amounts falling due within one year		( 443,194)		( 180,765)
Net current (liabilities)/assets		( 272,073)		34,361
Total assets less current liabilities		( 262,983)		53,277
Creditors: amounts falling due after more than one year		( 1,576,307)		( 2,020,141)
Accruals and deferred income		( 206,574)		( 176,650)
Net liabilities		( 2,045,864)		( 2,143,514)
Capital and reserves		( 2,045,864)		( 2,143,514)

For the financial year ending 31 December 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
• The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements;
• These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime;
• These financial statements have been delivered in accordance with the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Trichocare Diagnostics Ltd (registered number: 04091037) were approved and authorised for issue by the Board of Directors on 29 September 2025 and were signed on its behalf by:

Nicholas Plunkett Director

1. Company information

The Company is a private company limited by shares and is incorporated in the United Kingdom and registered in England and Wales (Company no. 04091037). The address of its registered office is Worlds End Studios 132-134, Lots Road, London, SW10 0RJ, United Kingdom.

2. Employees

	2024		2023
	Number		Number
Monthly average number of persons employed by the Company during the financial year, including directors	5		5

3. Directors’ benefits: advances, credit and guarantees

Advances

Included within current assets are advances of total directors loan of £78,683 owed from the directors (2023: £76,409). The amount is repayable on demand and attracts interest at 2.5%.

4. Guarantees and other financial commitments

Pensions

The Company operates a defined contribution pension scheme for the directors and senior employees. The assets of the scheme are held separately from those of the Company in an independently administered fund.

	2024		2023
	£		£
Unpaid contributions due to the fund (inc. in other creditors)	286		232

The Company has granted a floating charge over its assets to secure loans.

5. Creditors

Related party transactions

Included within creditors is a balance of £3,421 (2023: £1,100) owed to Trichocare Consulting Limited, a related party under common control

6. Going Concern

The directors note that the Company is loss making and in a net liabilities position. The Company is primarily funded through cash advances from shareholders and the directors have received confirmation that the shareholders will not request a repayment of the cash advances within 12 months of signing these financial statements, unless the Company has the ability to do so. The directors have secured further funds from its shareholders post year end. The shareholders have confirmed to financially support the business as required for a minimum period of 12 months from the date of these financial statements being signed and that they have the funds to do so. Based on the above and the financial support from the shareholders, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.